GS-6791

GS-6791 is a potent, selective, orally bioavailable small molecule degrader of interleukin-1 receptor-associated kinase 4 (IRAK4). It is designed to target both the scaffold and kinase functions of IRAK4, a master regulator in toll-like receptor (TLR) and interleukin-1 family receptor (IL-1R) signaling pathways that drive inflammatory responses. By degrading IRAK4 rather than merely inhibiting its kinase activity, GS-6791 achieves more complete blockade of pro-inflammatory signaling in immune and non-immune cells. Preclinical studies have shown rapid and sustained IRAK4 degradation across multiple human cell types—including disease-relevant tissues such as synovial fibroblasts—and robust efficacy in rodent models of arthritis. The drug is being developed for chronic inflammatory diseases including rheumatoid arthritis and atopic dermatitis by Nurix Therapeutics in collaboration with Gilead Sciences[1][2][3][5][6][7].

Other names

GS 6791GS6791GS-6791NX‑0479